TRACES
Regimen
- Experimental
- trilaciclib prior to etoposide + carboplatin
- Control
- placebo prior to etoposide + carboplatin
Population
Chinese extensive-stage small-cell lung cancer receiving first-line chemotherapy (myeloprotection focus)
Key finding
Cycle 1 DSN 0 vs 2 days (P=0.0003); mOS 12.0 vs 8.8 mo (HR 0.69, 95% CI 0.40-1.22); mPFS 4.8 vs 4.3 mo (HR 0.86, 95% CI 0.53-1.39)
Source: PMID 38224653
Timeline
Guideline citations
- NCCN SCLC (p.77)
- CSCO SCLC 2025 (p.72)⚠️ OCR source